Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Athena Appeal Decision Could Open ‘Floodgate’ For False Claims Litigation

This article was originally published in The Tan Sheet

Executive Summary

Lower court decisions that Athena Cosmetics’ RevitaLash products is an unapproved drug competing unfairly against Allergan's Latisse drug could have broader implications if the Supreme Court denies the firm's request for review. Already beleaguered by class actions following FDA warnings, firms could face more opportunistic lawsuits if federal courts are left to determine a product's intended use and regulatory status.

Advertisement

Related Content

Industry Roundup: Nicotine Exposure ANPR, Athena Petition Denied
Supreme Court Review Of Athena Cosmetics Case, Federal Preemption Argument Unlikely
Audio Feature: FDA Monitoring Cosmetic Claims, But Litigation Remains Biggest Threat
Cosmetics That ‘Do Something’ A Regulatory Compliance Challenge
Regulatory Roulette: Playing In Today’s Skin-Care Market A Gamble

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS107745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel